Ingalls & Snyder LLC’s AbbVie ABBV Stock Holding History

Ingalls & Snyder LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16,700	Closed	-$2.26M	–	465
2021 Q4	$2.26M	Hold	16,700	–	–	0.1%	149
2021 Q3	$1.8M	Hold	16,700	–	–	0.08%	170
2021 Q2	$1.88M	Buy	16,700 +100	+0.6%	+$11.3K	0.08%	173
2021 Q1	$1.8M	Buy	16,600 +6,700	+68%	+$717K	0.08%	172
2020 Q4	$1.06M	Buy	9,900 +6,600	+200%	+$634K	0.05%	214
2020 Q3	$289K	Buy	+3,300	New	+$311K	0.02%	303

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ingalls & Snyder LLC's ABBV Position: Q1 2026 in Review

Ingalls & Snyder LLC reduced its AbbVie (ABBV) stake by 0.61% in Q1 2026, selling an estimated $190K and leaving 139,627 shares worth $30.4M. The position accounts for 1.07% of the portfolio, ranked #21.

Ingalls & Snyder LLC first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $33.6M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Ingalls & Snyder LLC held 139,627 shares of AbbVie worth $30.4M as of Q1 2026.
Ingalls & Snyder LLC sold 857 AbbVie shares in Q1 2026, an estimated $190K.
AbbVie made up 1.07% of Ingalls & Snyder LLC's portfolio in Q1 2026, its #21 holding.
Ingalls & Snyder LLC first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Ingalls & Snyder LLC's AbbVie position peaked at $33.6M in Q3 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2026, filed 13 May 2026.